309 related articles for article (PubMed ID: 11016627)
1. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
[TBL] [Abstract][Full Text] [Related]
2. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
[TBL] [Abstract][Full Text] [Related]
3. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
[TBL] [Abstract][Full Text] [Related]
5. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
6. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics.
Okouneva T; Hill BT; Wilson L; Jordan MA
Mol Cancer Ther; 2003 May; 2(5):427-36. PubMed ID: 12748304
[TBL] [Abstract][Full Text] [Related]
7. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
[TBL] [Abstract][Full Text] [Related]
8. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.
Lobert S; Ingram JW; Hill BT; Correia JJ
Mol Pharmacol; 1998 May; 53(5):908-15. PubMed ID: 9584218
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
Lobert S; Puozzo C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
[TBL] [Abstract][Full Text] [Related]
10. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
Aparicio LM; Pulido EG; Gallego GA
Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.
Pourroy B; Honoré S; Pasquier E; Bourgarel-Rey V; Kruczynski A; Briand C; Braguer D
Cancer Res; 2006 Mar; 66(6):3256-63. PubMed ID: 16540678
[TBL] [Abstract][Full Text] [Related]
12. Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action.
Jordan MA; Walker D; de Arruda M; Barlozzari T; Panda D
Biochemistry; 1998 Dec; 37(50):17571-8. PubMed ID: 9860873
[TBL] [Abstract][Full Text] [Related]
13. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
14. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
15. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Colpaert F; Tarayre JP; Mouillard P; Fahy J; Hill BT
Cancer Chemother Pharmacol; 1998; 41(6):437-47. PubMed ID: 9554586
[TBL] [Abstract][Full Text] [Related]
16. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
Lobert S; Vulevic B; Correia JJ
Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
[TBL] [Abstract][Full Text] [Related]
17. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers.
Hill BT
Curr Pharm Des; 2001 Sep; 7(13):1199-212. PubMed ID: 11472262
[TBL] [Abstract][Full Text] [Related]
18. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway.
Pourroy B; Carré M; Honoré S; Bourgarel-Rey V; Kruczynski A; Briand C; Braguer D
Mol Pharmacol; 2004 Sep; 66(3):580-91. PubMed ID: 15322250
[TBL] [Abstract][Full Text] [Related]
19. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
[TBL] [Abstract][Full Text] [Related]
20. Low potency of taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism.
Derry WB; Wilson L; Jordan MA
Cancer Res; 1998 Mar; 58(6):1177-84. PubMed ID: 9515803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
